Currently Viewing:
Supplements Reducing the Risk of Cardiovascular Disease in Patients With Diabetes
The Burden of Cardiovascular Disease in Patients with Diabetes
Brooke Hudspeth, PharmD, CDE
Currently Reading
Antihyperglycemic Medications for Cardiovascular Disease Risk Reduction
Jennifer D. Goldman, PharmD, RPh, CDE, BC-ADM, FCCP
Participating Faculty
Posttest

Antihyperglycemic Medications for Cardiovascular Disease Risk Reduction

Jennifer D. Goldman, PharmD, RPh, CDE, BC-ADM, FCCP
In recognition of the substantial prevalence of cardiovascular disease-related comorbidities among patients with diabetes and the potential for some agents to increase this risk, evaluation of cardiovascular outcomes is now a standard component of late-stage clinical trials involving antihyperglycemic agents. While most agents are evaluated in noninferiority trials to establish a lack of cardiovascular-related harm,
a few agents have shown significant reductions in cardiovascular-related outcomes, including mortality.
Am J Manag Care. 2018;24:-S0

Become a Member to see the rest of this article and get access to all of our articles and resources. Membership is Free!

 
Copyright AJMC 2006-2018 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!